Myovant Sciences Company

Myovant Sciences developed Myfembree. Myfembree is a prescription medicine used to control heavy menstrual bleeding due to uterine fibroids in premenopausal women (before “change of life” or menopause).
Industry: Menstrual Health
Headquarters: London, England, United Kingdom
Founded Date: 01-01-2016
Employees Number: 101-250
Funding Status: IPO
Investors Number: 3
Total Funding: $340,000,000
Estimated Revenue: $10M to $50M
Last Funding Date: 2020-08-05
Last Funding Type: Post-IPO Debt

Visit Website
Register and Claim Ownership